TGF-β Modulated Pathways in Colorectal Cancer: New Potential Therapeutic Opportunities

Int J Mol Sci. 2024 Jul 5;25(13):7400. doi: 10.3390/ijms25137400.

Abstract

Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide, with 20% of patients presenting with metastatic disease at diagnosis. TGF-β signaling plays a crucial role in various cellular processes, including growth, differentiation, apoptosis, epithelial-mesenchymal transition (EMT), regulation of the extracellular matrix, angiogenesis, and immune responses. TGF-β signals through SMAD proteins, which are intracellular molecules that transmit TGF-β signals from the cell membrane to the nucleus. Alterations in the TGF-β pathway and mutations in SMAD proteins are common in metastatic CRC (mCRC), making them critical factors in CRC tumorigenesis. This review first analyzes normal TGF-β signaling and then investigates its role in CRC pathogenesis, highlighting the mechanisms through which TGF-β influences metastasis development. TGF-β promotes neoangiogenesis via VEGF overexpression, pericyte differentiation, and other mechanisms. Additionally, TGF-β affects various elements of the tumor microenvironment, including T cells, fibroblasts, and macrophages, promoting immunosuppression and metastasis. Given its strategic role in multiple processes, we explored different strategies to target TGF-β in mCRC patients, aiming to identify new therapeutic options.

Keywords: EMT; TGF-β; angiogenesis; colorectal cancer; microenvironment.

Publication types

  • Review

MeSH terms

  • Animals
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / metabolism
  • Colorectal Neoplasms* / pathology
  • Epithelial-Mesenchymal Transition
  • Humans
  • Neovascularization, Pathologic / metabolism
  • Signal Transduction*
  • Transforming Growth Factor beta* / metabolism
  • Tumor Microenvironment*

Substances

  • Transforming Growth Factor beta

Grants and funding

This research received no external funding.